Business Context and Reporting Period
Filing: Aileron Therapeutics, Inc. Form 10-Q for the three months ended March 31, 2022, filed May 5, 2022. The request metadata identifies Rein Therapeutics, Inc., but the filing text identifies the registrant as Aileron Therapeutics, Inc. (Nasdaq: ALRN).
Aileron is a clinical-stage oncology company developing ALRN-6924, an MDM2/MDMX dual inhibitor intended to protect healthy cells from chemotherapy in patients with p53-mutated cancers. The company has no approved products and has not generated product revenue.
Key Financial Metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $5.893 million | $4.316 million | Up $1.577 million |
| General and administrative expense | $2.528 million | $2.673 million | Down $0.145 million |
| Total operating expenses | $8.421 million | $6.989 million | Up $1.432 million |
| Net loss | $8.422 million | $6.975 million | Up $1.447 million |
| Net loss per share | $0.09 | $0.08 | Loss increased |
| Net cash used in operating activities | $7.800 million | $6.476 million | Use increased $1.324 million |
Operating and net loss margins are not meaningful because the company reported no revenue. Research and development represented approximately 70% of operating expenses, compared with approximately 62% in the prior-year quarter. Stock-based compensation was $0.689 million, versus $0.631 million.
At March 31, 2022, cash and cash equivalents were $7.449 million, investments were $30.626 million, and restricted cash was $0.025 million. Total cash, cash equivalents and investments were $38.075 million. Total assets were $40.255 million, total liabilities were $4.146 million, and stockholders’ equity was $36.109 million. The filing reports no debt outstanding; the prior PPP loan had been forgiven in 2021.
Cash used in operating activities was $7.800 million. Investing activities provided $11.649 million, primarily from $16.361 million of investment maturities or sales, partially offset by $4.712 million of investment purchases. Financing activities provided no cash in Q1 2022, compared with $55.604 million in Q1 2021 from common-stock issuance. Cash, cash equivalents and restricted cash increased by $3.849 million to $7.474 million.
Material Changes Versus the Prior Comparable Period
- R&D expense increased 37%, primarily due to greater clinical-development activity for ALRN-6924, startup activity for a planned breast-cancer trial, and higher manufacturing costs.
- G&A expense declined approximately 5% because of lower professional-services costs.
- Net loss increased approximately 21% as higher R&D spending more than offset the G&A reduction.
- Operating cash usage increased approximately 20%.
- Q1 2022 had no equity financing proceeds, whereas Q1 2021 included $55.6 million of net common-stock proceeds.
- Investments declined from $42.333 million at December 31, 2021 to $30.626 million at March 31, 2022, while cash and cash equivalents increased from $3.600 million to $7.449 million.
- Weighted-average shares outstanding increased to 90.674 million from 83.384 million, reflecting prior equity issuances and diluting per-share results.
Guidance, Outlook, Risks and Unusual Items
Management expects continuing operating losses and no product-sales revenue for the foreseeable future. Based on its current operating plan, the company expects its $38.1 million of cash, cash equivalents and investments at March 31, 2022 to fund operating expenses into the fourth quarter of 2023. Management also states that additional funding will be required to execute plans beyond the next twelve months and to complete development or commercialization of ALRN-6924.
The company planned to announce interim data from its Phase 1b NSCLC trial in June 2022 and intended to initiate a Phase 1b breast-cancer trial, subject to additional funding. COVID-19 had disrupted site activation and patient enrollment, particularly in Eastern Europe, and could continue to affect clinical timelines, supplies and capital raising.
- ALRN-6924 remains in clinical development and may never receive regulatory approval or achieve commercial success.
- Additional capital may be unavailable or available only on unfavorable terms, potentially causing delays, reductions or cancellations of clinical programs. Equity financing could dilute existing holders.
- The company received a Nasdaq deficiency notice in December 2021 because its stock bid price had remained below $1.00 for 30 consecutive business days. There is no assurance that compliance would be regained.
- The company relies on third-party manufacturers and a limited number of suppliers for drug materials, creating supply-interruption risk.
- At March 31, 2022, 12.935 million warrants and 11.957 million stock options were excluded from diluted loss per share because they were anti-dilutive. The warrants had a $2.00 exercise price.
- The company reported $5.500 million of unrecognized stock-based compensation expected to be recognized over a weighted-average period of 3.02 years.
- Potential license obligations include up to $7.7 million of milestones per licensed therapeutic product under the Harvard/Dana-Farber agreement and up to $6.4 million per licensed product under the Umicore agreement, plus royalties; no milestone liabilities were recorded at quarter-end.
Investor Verification Checklist
- Confirm the issuer identity: the supplied metadata says Rein Therapeutics, while the filing itself is for Aileron Therapeutics, Inc.
- Verify the cash runway assumption through Q4 2023 against current quarterly cash burn, clinical-trial spending and financing availability.
- Review subsequent clinical data, including the planned June 2022 NSCLC interim update and the status of the breast-cancer trial.
- Check whether the Nasdaq minimum-bid-price deficiency was cured or resulted in delisting action.
- Assess future dilution from the ATM facility, the Lincoln Park equity line, stock options and warrants.
- Evaluate the effect of COVID-19, patient-enrollment delays and third-party manufacturing constraints on development timelines.
- Review the company’s latest filing for changes in cash, investments, accumulated deficit, going-concern disclosures and financing plans.